<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101623795</journal-id>
<journal-id journal-id-type="pubmed-jr-id">42112</journal-id>
<journal-id journal-id-type="nlm-ta">Arthritis Rheumatol</journal-id>
<journal-title-group>
<journal-title>Arthritis &amp; rheumatology (Hoboken, N.J.)</journal-title>
</journal-title-group>
<issn pub-type="ppub">2326-5191</issn>
<issn pub-type="epub">2326-5205</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30009530</article-id>
<article-id pub-id-type="pmc">6310104</article-id>
<article-id pub-id-type="doi">10.1002/art.40672</article-id>
<article-id pub-id-type="manuscript">NIHMS981541</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Macrophage migration inhibitory factor regulates U1-snRNP immune complex mediated activation of the NLRP3 inflammasome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Shin</surname>
<given-names>Min Sun</given-names>
</name>
<degrees>Ph.D</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kang</surname>
<given-names>Youna</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wahl</surname>
<given-names>Elizabeth R.</given-names>
</name>
<degrees>M.D.</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Park</surname>
<given-names>Hong-Jai</given-names>
</name>
<degrees>Ph.D</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lazova</surname>
<given-names>Rossitza</given-names>
</name>
<degrees>M.D.</degrees>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Leng</surname>
<given-names>Lin</given-names>
</name>
<degrees>Ph.D</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mamula</surname>
<given-names>Mark</given-names>
</name>
<degrees>Ph.D</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Krishnaswamy</surname>
<given-names>Smita</given-names>
</name>
<degrees>Ph.D</degrees>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bucala</surname>
<given-names>Richard</given-names>
</name>
<degrees>M.D., Ph.D</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kang</surname>
<given-names>Insoo</given-names>
</name>
<degrees>M.D.</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06520, USA</aff>
<aff id="A2">
<label>2</label>Department of Dermatopathology, Yale University School of Medicine, New Haven, Connecticut 06520, USA</aff>
<aff id="A3">
<label>3</label>California Skin Institute, San Jose, California 95124</aff>
<aff id="A4">
<label>4</label>Department of Genetics, Yale University School of Medicine, New Haven, Connecticut 06520, USA</aff>
<author-notes>
<corresp id="FN1">Correspondence: Insoo Kang, Department of Internal Medicine, Section of Rheumatology, Yale School of Medicine, 300 Cedar Street, New Haven, CT 06520, Telephone: +01-203-785-6678, Fax: +01-203-785-7053, <email>Insoo.kang@yale.edu</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p><bold>Conflict of Interest:</bold> Dr. Bucala is an inventor of MIF antagonists and has received past licensing royalties from Baxter Healthcare and Debiopharm SA.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>14</day>
<month>7</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>04</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>1</month>
<year>2020</year>
</pub-date>
<volume>71</volume>
<issue>1</issue>
<fpage>109</fpage>
<lpage>120</lpage>
<!--elocation-id from pubmed: 10.1002/art.40672-->
<abstract>
<sec id="S1">
<title>Objective</title>
<p id="P1">High expression alleles of macrophage migration inhibitory factor (MIF) are linked genetically to SLE disease severity. The U1-snRNP (snRNP) immune complex containing U1-snRNP and anti-U1-snRNP antibodies, which are found in SLE, activates the NLRP3 inflammasome comprised of NLRP3, ASC, and procaspase-1 in human monocytes, leading to the production of IL-1β. The role of the snRNP immune complex in upregulating the MIF and its interface with the NLRP3 inflammasome were investigated.</p>
</sec>
<sec id="S2">
<title>Methods</title>
<p id="P2">MIF, IL-1β, NLRP3, caspase-1, ASC, and MIF receptors were analyzed in human monocytes incubated with or without the snRNP immune complex by ELISA, Western blot, qPCR, and CyTOF. MIF pathway responses were probed with the novel small molecule antagonist MIF098.</p>
</sec>
<sec id="S3">
<title>Results</title>
<p id="P3">The snRNP immune complex induced the production of MIF and IL-1β from human monocytes. High-dimensional single cell CyTOF analysis established MIF regulation of inflammasome activation, including a quantitative relationship in MIF, its receptors, and IL-1β, in monocytes. MIF098, which blocks MIF binding to its cognate receptor, suppressed IL-1β production and NLRP3 upregulation, a rate-limiting step in activating the NLRP3 inflammasome, as well as caspase-1 activation in snRNP immune complex-stimulated human monocytes.</p>
</sec>
<sec id="S4">
<title>Conclusion</title>
<p id="P4">The U1-snRNP immune complex is a specific stimulus of MIF production in human monocytes, with MIF having an upstream role in defining the inflammatory characteristics of activated monocytes by regulating NLRP3 inflammasome activation and downstream IL-1β production. These findings provide mechanistic insight and a therapeutic rationale for targeting MIF in subgroups of lupus patients, such as high genotypic <italic>MIF</italic> expressers or those with anti-snRNP antibodies.</p>
</sec>
</abstract>
<kwd-group>
<kwd>macrophage migration inhibitory factor (MIF)</kwd>
<kwd>systemic lupus erythematosus (SLE)</kwd>
<kwd>NLRP3</kwd>
<kwd>inflammasome</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>